Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
A phase 2 trial of Futibatinib, Pembrolizumab, Cisplatin and Oxaliplatin in oesophageal cancer and pancreatic ductal adenocarcinoma, run by Taiho Oncology, Inc., active and no longer recruiting.
Overview
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors is a phase 2 interventional study registered as NCT05945823 by Taiho Oncology, Inc., with 53 participants enrolled, started 2023-07-13 and due to reach its primary completion in 2026-10-01. Interventions recorded: Futibatinib, Pembrolizumab, Cisplatin, 5-FU, Oxaliplatin and Leucovorin.
Similar pages
not linked directly; found by shared links- TrialFutibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer
Shares Araris Biotech (Taiho), Futibatinib, Cisplatin, Pembrolizumab and the tag pipeline.
- TrialSubstudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
Shares Oxaliplatin, Oesophageal cancer, Pembrolizumab and the tag pipeline.
- TrialStudy of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities
Shares Araris Biotech (Taiho) and the tag pipeline.
- TrialA Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.
Shares Araris Biotech (Taiho) and the tag pipeline.
- TrialStudy of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement
Shares Araris Biotech (Taiho) and the tag pipeline.
- TrialPhase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas
Shares Araris Biotech (Taiho) and the tag pipeline.
- TrialSubstudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
Shares Oxaliplatin, Oesophageal cancer, Pembrolizumab and the tag pipeline.
- TrialA Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors
Shares Oxaliplatin, Pembrolizumab and the tag pipeline.